The total number of records retrieved from this search are 71. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_4706	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4707	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result98% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4708	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4709	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result75% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4710	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4721	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.001 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4722	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4723	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4724	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result50% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4725	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result25% cell viability	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4736	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.001 MOI	In-vitro result1% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4737	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4738	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4739	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4740	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell death	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4751	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4752	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4753	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4754	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4763	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result90% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4764	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4765	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result75% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4766	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result65% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4775	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.01 MOI	In-vitro result25% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4776	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration0.1 MOI	In-vitro result20% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4777	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration1 MOI	In-vitro result15% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4778	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result10% cell survival	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4787	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4788	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4789	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result18% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4790	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4791	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4792	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result10% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4793	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4794	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result50% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4795	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4796	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result40% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4797	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4798	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result1% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4799	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result30% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4800	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result2% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4801	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result2% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4832	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4833	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4834	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result60% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4835	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4836	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4837	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result10% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4838	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result100% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4839	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4840	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result5% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4841	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result90% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4842	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result50% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4843	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result1% cell viability after 4 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4844	Virus nameMyxoma virus	Virus strainwild type	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result70% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4845	Virus nameVaccinia virus	Virus strainvvDD	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of TK gene and vaccinia growth factor	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result20% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_4846	Virus nameMaraba virus	Virus strainwild type	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8	Concentration of cell line50000 cells per well	In-vitro toxicityNA	AssayCell titer Glo luminiscent assay	In-vitro virus concentration10 MOI	In-vitro result1% cell viability after 5 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27119108
IDOV_5291	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHeyA8	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration0.1 PFU	In-vitro result100% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5292	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHeyA8	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration0.33 PFU	In-vitro result98% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5293	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHeyA8	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration1 PFU	In-vitro result95% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5294	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHeyA8	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration3.3 PFU	In-vitro result77% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5295	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHeyA8	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration10 PFU	In-vitro result60% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5296	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHeyA8	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration33 PFU	In-vitro result39% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5297	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHeyA8	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration100 PFU	In-vitro result22% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5298	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration0.1 PFU	In-vitro result100% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5299	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration0.33 PFU	In-vitro result38% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5300	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration1 PFU	In-vitro result10% cell viable	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5301	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration3.3 PFU	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5302	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration10 PFU	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5303	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration33 PFU	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340
IDOV_5304	Virus nameHerpes simplex virus	Virus strainM032	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for both copies of gamma 34.5 gene and expressing human IL-12 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine IL-12	Source of cell lineNA	Origin of cell lineHuman ovarian cancer cell line	Cell lineHEYA8 MDR	Concentration of cell line4000 cells per well	In-vitro toxicityNA	AssayAlamar blue assay	In-vitro virus concentration100 PFU	In-vitro result100% cell killing	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedNA	Immunogenic effectTumor specific T cell response induced	Clinical trialNA	PMID27784340